Halozyme Therapeutics (HALO) EBT (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly EBT of $180.3 million for Q1 2026, up 25.38% year-over-year from $143.8 million in Q1 2025, and up 278.81% quarter-over-quarter from -$100.8 million in Q4 2025.
Halozyme Therapeutics (HALO) EBT (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported EBT for 17 consecutive years, with $180.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT rose 25.38% year-over-year to $180.3 million; the TTM figure through Mar 2026 stood at $503.4 million (down 16.79% YoY), while the FY2025 annual figure was $466.9 million, down 16.2% from the prior year.
- EBT grew to $180.3 million in Q1 2026 per HALO's latest filing, from -$100.8 million in the prior quarter.
- Across five years, EBT topped out at $219.0 million in Q3 2025 and bottomed at -$100.8 million in Q4 2025.
- Historically, EBT has averaged $106.0 million across 5 years, with a median of $101.2 million in 2023.
- Annual changes were most pronounced in 2023 — EBT soared 210.41% — and 2025, when it plunged 156.59%.
- Halozyme Therapeutics' EBT stood at $70.8 million in 2022, then jumped by 42.92% to $101.2 million in 2023, then surged by 76.14% to $178.2 million in 2024, then slumped by 156.59% to -$100.8 million in 2025, then soared by 278.81% to $180.3 million in 2026.
- Business Quant data shows HALO's EBT at $180.3 million in Q1 2026, -$100.8 million in Q4 2025, and $219.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 284.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 284.90 Mn |
| Mar 31, 2026 | 180.33 Mn |
| Dec 31, 2025 | -100.85 Mn |
| Sep 30, 2025 | 218.96 Mn |
| Jun 30, 2025 | 204.94 Mn |
| Mar 31, 2025 | 143.83 Mn |
| Dec 31, 2024 | 178.21 Mn |
| Sep 30, 2024 | 165.15 Mn |
| Jun 30, 2024 | 117.74 Mn |
| Mar 31, 2024 | 96.03 Mn |
| Dec 31, 2023 | 101.18 Mn |
| Sep 30, 2023 | 101.76 Mn |
| Jun 30, 2023 | 93.16 Mn |
| Mar 31, 2023 | 52.24 Mn |
| Dec 31, 2022 | 70.79 Mn |
| Sep 30, 2022 | 73.71 Mn |
| Jun 30, 2022 | 30.01 Mn |
| Mar 31, 2022 | 74.41 Mn |
| Dec 31, 2021 | 54.81 Mn |
| Sep 30, 2021 | 74.11 Mn |